1. those who have history of hypersensitivity to the components of the investigational product or the reference product 2. those with viral or bacterial pneumonia other than expected indications 3. patients receiving organ transplants within 6 months of screening 4. patients with a history of pulmonary embolism 5. patients who have indications of investigational products as an underlying disease (ex. hiv patients in the clinical study of antiretroviral drugs) 6. patients who are pregnant or lactating 7. those who are determined by the investigator to be unsuitable for participation in the clinical trial due to other reasons including the results of the clinical laboratory test. 8. patients participating in other clinical studies

1. those who have history of hypersensitivity to the components of the investigational product or the reference product 2. those with viral or bacterial pneumonia other than expected indications 3. patients receiving organ transplants within 6 months of screening 4. patients with a history of pulmonary embolism 5. patients who have indications of investigational products as an underlying disease (ex. hiv patients in the clinical study of antiretroviral drugs) 6. patients who are pregnant or lactating 7. those who are determined by the investigator to be unsuitable for participation in the clinical trial due to other reasons including the results of the clinical laboratory test. 8. patients participating in other clinical studies

those who have history of hypersensitivity to the components of the investigational product or the reference product those with viral or bacterial pneumonia other than expected indications patients receiving organ transplants within 6 months of screening patients with a history of pulmonary embolism patients who have indications of investigational products as an underlying disease (ex. hiv patients in the clinical study of antiretroviral drugs) patients who are pregnant or lactating those who are determined by the investigator to be unsuitable for participation in the clinical trial due to other reasons including the results of the clinical laboratory test. patients participating in other clinical studies

those who have history of hypersensitivity to the components of the investigational product or the reference product those with viral or bacterial pneumonia other than expected indications patients receiving organ transplants within 6 months of screening patients with a history of pulmonary embolism patients who have indications of investigational products as an underlying disease (ex. hiv patients in the clinical study of antiretroviral drugs) patients who are pregnant or lactating those who are determined by the investigator to be unsuitable for participation in the clinical trial due to other reasons including the results of the clinical laboratory test. patients participating in other clinical studies

1. those who have history of hypersensitivity to the components of the investigational product or the reference product 2. those with viral or bacterial pneumonia other than expected indications 3. patients receiving organ transplants within 6 months of screening 4. patients with a history of pulmonary embolism 5. patients who have indications of investigational products as an underlying disease (ex. hiv patients in the clinical study of antiretroviral drugs) 6. patients who are pregnant or lactating 7. those who are determined by the investigator to be unsuitable for participation in the clinical trial due to other reasons including the results of the clinical laboratory test. 8. patients participating in other clinical studies

1. those who have history of hypersensitivity to the components of the investigational product or the reference product 2. those with viral or bacterial pneumonia other than expected indications 3. patients receiving organ transplants within 6 months of screening 4. patients with a history of pulmonary embolism 5. patients who have indications of investigational products as an underlying disease (ex. hiv patients in the clinical study of antiretroviral drugs) 6. patients who are pregnant or lactating 7. those who are determined by the investigator to be unsuitable for participation in the clinical trial due to other reasons including the results of the clinical laboratory test. 8. patients participating in other clinical studies